For semaglutide, while the core patent (protecting the molecule itself) expires in 2026, Novo Nordisk has likely filed secondary patents on aspects like formulations, dosage regimens, or delivery mechanismspotentially extending protection into the 2030s
Some oral medications
But now I am in a season where I want to do things that I enjoy and that are good for me
Individuals with obesity, compared to those with a healthy weight, have increased risk for several serious diseases and conditions, including hypertension, asthma, heart disease, stroke, type 2 diabetes, many cancers, breathing difficulty, and joint issues
This is where most standard supplements fail
What youll learn This guide walks through why compounded tirzepatide was pulled, how Mounjaro compares, and whether switching makes sense for your goals